Nqoba Tsabedze
Overview
Explore the profile of Nqoba Tsabedze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Snyman J, Gumedze F, Jones E, Alaba O, Tsabedze N, Vira A, et al.
Adv Ther
. 2024 Nov;
42(1):552-555.
PMID: 39560898
No abstract available.
2.
Mogashoa V, Mpanya D, Tsabedze N
Thromb J
. 2024 Oct;
22(1):94.
PMID: 39472898
Background: Atrial fibrillation is a growing epidemic in Africa. Anticoagulation, considered the backbone for non-valvular atrial fibrillation (NVAF) management, is limited to warfarin as the mainstay of available anticoagulation therapy...
3.
Mpanya D, Sathekge M, Klug E, Damelin J, More S, Hadebe B, et al.
Front Nucl Med
. 2024 Oct;
3:1224905.
PMID: 39355018
Gallium-68 fibroblast activation protein inhibitor [(Ga)Ga-FAPI] is a new radiopharmaceutical positioning itself as the preferred agent in patients with malignant tumours, competing with 2-Deoxy-2-[18F]fluoro-d-glucose [2-(F)FDG] using positron emission tomography (PET)....
4.
Sigauke F, Ntsinjana H, Tsabedze N
Heart Fail Rev
. 2024 Sep;
29(6):1261-1278.
PMID: 39348083
Cardiovascular disease is a major non-communicable disease globally, with increasing prevalence, posing a significant public health challenge. It is the leading non-obstetric cause of perinatal morbidity and mortality, with a...
5.
Adamu U, Badianyama M, Mpanya D, Maseko M, Tsabedze N
JMIR Res Protoc
. 2024 May;
13:e53905.
PMID: 38781584
Background: Heart failure (HF) is a significant health problem that is often associated with major morbidity and mortality. Metabolic abnormalities occur in HF and may be used to identify individuals...
6.
McCutcheon K, Nqebelele U, Murray L, Thomas T, Mpanya D, Tsabedze N
Circ Res
. 2024 May;
134(11):1636-1660.
PMID: 38781295
Contemporary World Health Organization data indicates that ≈39 million people are living with the human immunodeficiency virus. Of these, 24 million have been reported to have successfully accessed combination antiretroviral...
7.
Taddei S, Tsabedze N, Tan R
Curr Med Res Opin
. 2024 Apr;
40(sup1):15-23.
PMID: 38597065
β-blockers are a heterogeneous class, with individual agents distinguished by selectivity for β- vs. β- and α-adrenoceptors, presence or absence of partial agonist activity at one of more β-receptor subtype,...
8.
Tsabedze N, Naicker R, Mrabeti S
Front Cardiovasc Med
. 2024 Feb;
10:1280953.
PMID: 38322274
Introduction: Compared with first-line antihypertensives, beta-blockers (BB) have been reported to lower the central aortic blood pressure suboptimally and are associated with increased stroke risk. This observation has not been...
9.
Mhlaba L, Mpanya D, Tsabedze N
Front Clin Diabetes Healthc
. 2023 Nov;
4:1258792.
PMID: 38028982
Background: Type 2 diabetes mellitus (T2DM) patients with coronary artery disease (CAD) have an increased risk of recurrent cardiovascular events. These patients require optimal glucose control to prevent the progression...
10.
Snyman J, Gumedze F, Jones E, Alaba O, Tsabedze N, Vira A, et al.
Adv Ther
. 2023 Sep;
40(11):5076-5089.
PMID: 37730949
Introduction: Differences in class or molecule-specific effects between renin-angiotensin-aldosterone system (RAAS) inhibitors have not been conclusively demonstrated. This study used South African data to assess clinical and cost outcomes of...